Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements
Authors:
Open Access
- 17 March 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 109 (6)
Abstract
There is a wide range of adaptive elements of clinical trial design (some old and some new), with differing advantages and disadvantages. Classical interim monitoring, which adapts the design based on early evidence of superiority or futility of a treatment arm, has long been known to be extremely useful. A more recent application of interim monitoring is in the use of phase II/III designs, which can be very effective (especially in the setting of multiple experimental treatments and a reliable intermediate end point) but do have the cost of having to commit earlier to the phase III question than if separate phase II and phase III trials were performed. Outcome-adaptive randomization is an older technique that has recently regained attention; it increases trial complexity and duration without offering substantial benefits to the patients in the trial. The use of adaptive trials with biomarkers is new and has great potential for efficiently identifying patients who will be helped most by specific treatments. Master protocols in which trial arms and treatment questions are added to an ongoing trial can be especially efficient in the biomarker setting, where patients are screened for entry into different subtrials based on evolving knowledge about targeted therapies. A discussion of three recent adaptive clinical trials (BATTLE-2, I-SPY 2, and FOCUS4) highlights the issues.Keywords
This publication has 52 references indexed in Scilit:
- Bayesian clinical trials in actionStatistics in Medicine, 2012
- Design Issues in Randomized Phase II/III TrialsJournal of Clinical Oncology, 2012
- Biostatistical Considerations in Development of Biomarker-Based Tests to Guide Treatment DecisionsStatistics in Biopharmaceutical Research, 2011
- Using randomization tests to preserve type I error with response adaptive and covariate adaptive randomizationStatistics & Probability Letters, 2011
- Outcome-Adaptive Randomization: Is It Useful?Journal of Clinical Oncology, 2011
- Randomized Clinical Trials With Biomarkers: Design IssuesJNCI: Journal of the National Cancer Institute, 2010
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- Multi-Arm Clinical Trials of New Agents: Some Design ConsiderationsClinical Cancer Research, 2008
- Stopping when the experimental regimen does not appear to helpStatistics in Medicine, 1994
- The Randomized Play-the-Winner Rule in Medical TrialsJournal of the American Statistical Association, 1978